Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers

BMC Pharmacology and Toxicology volume 20, Article number: 1 (2019) Cite this article

Abstract

Background

2-Hydroxybenzylamine (2-HOBA) is a selective scavenger of dicarbonyl electrophiles that protects proteins and lipids from being modified by these electrophiles. It is currently being developed for use as a nutritional supplement to help maintain good health and protect against the development of conditions associated with dicarbonyl electrophile formation, such as the cognitive decline associated with Mild Cognitive Impairment and Alzheimer’s disease.

Methods

In this first-in-human study, the safety, tolerability, and pharmacokinetics of six ascending single oral doses of 2-HOBA acetate were tested in eighteen healthy human volunteers.

Results

Reported adverse events were mild and considered unlikely to be related to 2-HOBA. There were no clinically significant changes in vital signs, ECG recordings, or clinical laboratory parameters. 2-HOBA was fairly rapidly absorbed, with a tmax of 1–2 h, and eliminated, with a t1/2 of approximately 2 h. Both tmax and t1/2 were independent of dose level, while Cmax and AUC increased proportionally with dose level.

Conclusions

2-HOBA acetate was safe and well-tolerated at doses up to 825 mg in healthy human volunteers, positioning it as a good candidate for continued development as a nutritional supplement.

Trial registration

This study is registered at ClinicalTrials.gov (NCT03176940).

Peer Review reports

Background

Inflammation and oxidative stress, which have been implicated as potential mediators in the development and progression of many conditions, result in the formation of extremely reactive dicarbonyl electrophiles. These dicarbonyls react with lysine residues to form protein adducts that can alter the function and interactions of various cellular proteins [1, 2]. Proteins adducted by one such highly reactive dicarbonyl, isolevuglandin, are found at elevated levels in a number of health conditions, including Alzheimer’s disease [3], atherosclerosis [4], hypertension [5], and liver disease [6]. Dicarbonyl electrophiles also have been mechanistically associated with the development of Alzheimer’s disease, as they have been shown to enhance the oligomerization and neurotoxicity of amyloid beta [7, 8].

Fortunately, dicarbonyl electrophiles can be specifically neutralized by a novel class of scavenger molecules [9]. One of these scavenger molecules, 2-hydroxybenzylamine (2-HOBA), reacts substantially faster with these dicarbonyls than does lysine, preventing dicarbonly-associated protein modifications. 2-HOBA, which is naturally found in buckwheat [10], is orally available [11] and crosses the blood brain barrier, resulting in brain 2-HOBA levels approximately twice as high as plasma levels [11]. Administration of 2-HOBA prevented the age-associated working memory deficit in the hApoE4 mouse model [12], suggesting this inhibition of dicarbonyl protein modification could help maintain hippocampal function.

A series of preclinical safety studies, including acute and short-term rodent studies [13] as well as in vitro safety pharmacology studies [14] and sub-chronic rat [15] and rabbit studies [16] indicated no toxicity concerns of 2-HOBA acetate within the therapeutic dose range. Thus, the objective of the present investigation was to perform the initial evaluation of 2-HOBA acetate in humans. This first-in-human study assessed the safety, tolerability, and pharmacokinetics of single ascending doses of 2-HOBA acetate in healthy humans.

Methods

This study is registered at ClinicalTrials.gov (NCT03176940). The study protocol was approved by the Vanderbilt University Institutional Review Board. All participants provided written informed consent before participating in the study.

Subjects

Healthy male and non-pregnant female volunteers over 18 years of age were eligible to participate. Subjects were not permitted to take any medications 2 weeks prior to or during the study. Exclusion criteria included known cardiac, kidney, or hepatic disease; presence of diseases that could manifest morbidity or symptoms/signs that could confound interpretation of the study results; the need to discontinue any drug administered as standard of care treatment; and the unwillingness or inability to use approved birth-control methods.

Compound

2-HOBA (as the acetate salt, CAS 1206675–01-5) was obtained from TSI (China) Co., Ltd. (Shanghai, China). A commercial production lot was used (Lot 16120312). Our laboratory verified the purity of the commercial lot to be > 99% via HPLC and NMR spectroscopy. Hard gel capsules (Capsugel, Jiangsu, China) containing 50, 110, and 412.5 mg of 2-HOBA acetate (corresponding to 34, 75, and 281 mg 2-HOBA) were prepared by TSI (China) Co., Ltd. Determinations of average fill weight, uniformity of weight, disintegration, 2-HOBA content, acetate content, and microbial and analytical tests were within all specification limits.

Study design

This study was an open-label, single ascending dose study designed to assess pharmacokinetics, safety, and tolerability of single doses of 2-HOBA acetate. A 3 + 3 clinical trial design with a modified Fibonacci sequence dosing scheme [17] was used with a starting dose of 50 mg; thereafter, dosages were increased to 100, 200, 330, 550, and 825 mg. These doses of 2-HOBA acetate correspond to 34, 68, 136, 224, 373, and 560 mg 2-HOBA. Each dose escalation was initiated only after reviewing safety data from all subjects receiving the previous dose.

Subjects were admitted to the Vanderbilt University Clinical Research Center and remained on the unit for 24 h after administering 2-HOBA acetate orally in capsules to participants. Though this study did not include a placebo control, staff nurses and participants were blinded to the capsule dosage content. Subjects were monitored at protocol-defined intervals for 24 h after administration of 2-HOBA. Safety assessments included vital signs (heart rate, respiration rate, blood pressure, and SpO2), clinical laboratory parameters (blood biochemistry, hematology, and urinalysis), 12-lead ECGs, and potential adverse event assessments. All adverse events were recorded, regardless of whether they were considered to be study-related.

Pharmacokinetic sampling and analysis

Blood samples for pharmacokinetic analyses were collected at baseline, 0.5, 1, 2, 4, 8, and 24 h after 2-HOBA acetate administration for all dose levels. A 0.25-h sample was only collected for dosages ≤200 mg, and a 6-h sample was only collected for dosages ≥330 mg. Plasma concentrations of 2-HOBA as well as the primary metabolite of 2-HOBA, salicylic acid, were determined for each time point.

[2H4]-2-HOBA, prepared by Dr. Venkataraman Amarnath as previously described [11], was used as an internal standard. An internal standard solution (100 ng/mL) of ([2H4]-2-HOBA was prepared in acetonitrile and added to all standards, quality control samples, and patient samples. Standard and quality control samples of 1 mg/mL 2-HOBA were prepared in water. Eight standard curve samples (5, 10, 20, 100, 200, 1000, 2000, and 5000 ng/mL) were prepared with blank human plasma (Bioreclamation, Westbury, NY). In addition, three quality control samples (15, 300, and 3000 ng/mL) were prepared in blank human plasma. Plasma samples were allowed to thaw at room temperature and then vortexed. Internal standard solution (400 μL) and 100 μL of either plasma, quality controls, or standards were added and mixed in a protein precipitation filter 96-well plate (Phenomenex, Torrance, CA). The solution was eluted into a 96-well plate using a positive pressure manifold and then dried under nitrogen gas at 40 °C. The samples were then reconstituted in 97/3 v/v water/acetonitrile with 10 mM ammonium formate for analysis. Liquid chromatography tandem mass spectrometry analysis of 2-HOBA was performed with Shimadzu Nexera X2 LC-30 AD pumps, column oven, and degasser (Kyoto, Japan) (column: C18 2.1 × 50 mm, 1.7 μm, Phenomenex, Torrance, CA) coupled with a Sciex QTrap 5500 mass spectrometer with TurboV ion source (Framingham, MA). Quantification of 2-HOBA was performed using electrospray ionization in positive ionization mode. The column temperature was set to 60 °C and the flow rate was 0.5 mL/min. A gradient of 3–90 %B from 0 to 0.90 min was established by using a mobile phase A of 10 mM ammonium formate in water and mobile phase B of 1% formic acid in acetonitrile. Quantification of 2-HOBA was validated over the range of 5–5000 ng/mL, with within-run precision of 3.7–7.0%, bias − 9.7 – 2.8 and between run precision of 4.4–6.2%, bias − 7.1 – 1.64. All standards and quality control samples met acceptance criteria (standard curve R2 > 0.90, 66.7% of all QC samples and at least 50% at each concentration within 15% of nominal concentration).

Plasma concentration-time data was imported into Phoenix WinNonlin® 8.0 software (Certara USA, Inc., Princeton, NJ) to estimate the oral pharmacokinetic parameters of 2-HOBA from individual subjects at each dose level. Non-compartmental analysis using Model 200 (Plasma; Single Extravascular Dose; Linear Log Trapezoidal Method) was performed on each plasma concentration-time profile to estimate individual pharmacokinetic parameters – half-life, area under the concentration-time curve (AUC), maximum observed plasma concentration (Cmax), and the time to reach the maximum observed plasma concentration (Tmax).

Statistical analyses

Descriptive statistics (means, standard deviations, standard error) were used for demographics, safety, and pharmacokinetic assessments.

Results

Study population

A total of 18 volunteers were enrolled in and successfully completed the study (3 subjects at each dose level). Subject demographics are provided in Table 1 and were similar across dose groups.

Table 1 Demographic Characteristics
Full size table

Safety

All reported adverse events are summarized in Table 2. Five participants (28%) reported at least 1 adverse event during the study. The most common reported adverse event (2 incidences) was frequent urination (2 subjects, 11%). All adverse events were mild in intensity. No adverse events were determined to be study-related, and there was no dose-dependent increase in adverse event frequency or severity. No clinically significant changes in ECG recordings, vital signs, or laboratory parameters that were considered to be related to 2-HOBA were observed. There were no serious adverse events or deaths.

Table 2 Summary of reported adverse events by dose
Full size table

Pharmacokinetics

Mean 2-HOBA plasma concentration-time profiles and pharmacokinetic parameter estimates are shown in Fig. 1 and Table 3, respectively. Following oral administration of single doses of 2-HOBA, dose-dependent changes were observed for maximal plasma concentration (Cmax) and area under the concentration-time curve (AUC). The mean time to reach Cmax was 1.6 h and the mean half-life of 2-HOBA was 2.1 h.

Fig. 1
figure 1

2-Hydroxybenzylamine (2-HOBA) plasma concentrations after oral administration of 2-HOBA acetate. 2-HOBA plasma concentration was measured for 24 h after oral administration of six ascending single doses of 2-HOBA acetate in healthy subjects (n=3 per dose level). Blood samples for pharmacokinetic analyses were collected at baseline, 0.5, 1, 2, 4, 8, and 24 h after 2-HOBA acetate administration for all dose levels. A 0.25-hour sample was only collected for dosages ≤ 200 mg, and a 6-h sample was only collected for dosages ≥ 330 mg. No 2-HOBA was detectable prior to administration (time 0) or at 24 h post-administration (assay limit of detection = 5 ng/mL)

Full size image
Table 3 Mean 2-hydroxybenzylamine pharmacokinetic parameters after a single oral dose
Full size table

Plasma concentrations of the primary metabolite of 2-HOBA, salicylic acid were also measured. Systemic exposure to salicylic acid following oral administration of single doses of 2-HOBA acetate at each dose level is shown in Additional file 1: Figure S1 and quantified in Additional file 1: Table S1, both located in Additional file 1. Following oral administration of 2-HOBA, dose-dependent changes were observed in the systemic exposure (Cmax and AUC) of salicylic acid. The tmax for salicylic acid ranged from 2.67 to 4.67 h and tended to increase as the 2-HOBA dose increased.

Discussion

The results of this first-in-human study demonstrate that single doses of 2-HOBA acetate up to 825 mg were well tolerated by healthy individuals. No serious adverse events or dose-limiting adverse events were observed. All reported adverse events were mild in intensity and unlikely to be 2-HOBA-related. There were no clinically significant findings in vital signs, ECG recordings, or clinical laboratory parameters.

After oral administration of a single dose, 2-HOBA was readily absorbed, with a tmax of 1 to 2 h after administration at all dose levels. Systemic exposure to 2-HOBA was dose-dependent, as was the exposure of salicylic acid, the primary metabolite of 2-HOBA. The pharmacokinetic values for salicylic acid observed in this study were similar to those observed after single doses of 40.5–324 mg of acetylsalicylic acid (aspirin) [18], which is rapidly hydrolyzed to salicylic acid after oral administration. This suggests the tested dose range of 2-HOBA acetate induces similar salicylic acid exposure to that observed with low-to-moderate doses of acetylsalicylic acid.

The terminal slopes of the log-linear phase of the plasma-concentration time profiles for 2-HOBA were parallel and independent of dose, which is reflected in the similar half-life at each dose level. 2-HOBA appears to have a relatively short half-life (~ 2 h). These pharmacokinetic properties of 2-HOBA in humans are generally similar to those previously observed in mice [11]. Clearance and volume of distribution are not reported due to the unknown value of F (bioavailability) following oral administration of 2-HOBA acetate.

These observations supporting that orally administered 2-HOBA acetate is well-tolerated and safe in humans comprise an important addition to our portfolio of preclinical 2-HOBA safety data. The good safety profile to date combined with the preclinical efficacy established in mice at risk for age-related cognitive decline support continued development of 2-HOBA as a nutritional supplement to enhance cognitive health and support healthy brain aging. Additionally, although our development of 2-HOBA has been primarily focused on the cognitive decline associated with Mild Cognitive Impairment or Alzheimer’s disease, there is also evidence for beneficial effects of 2-HOBA on other aspects of neurological health associated with the accumulation of dicarbonyl adducts, such as seizure-associated cognitive dysfunction. 2-HOBA attenuated neuronal loss, astrogliosis, and spatial and reference memory deficits in mouse models of epilepsy without affecting epileptic injury [19].

There is also evidence for beneficial effects of 2-HOBA on cardiovascular health, most notably blood pressure. 2-HOBA attenuated angiotensin-II induced hypertension and renal damage in mice [5], normalized blood pressure in a murine model of hypertension [20], and prevented the development of pulmonary arterial hypertension in mice with mitochondrial oxidant injury [21]. Exposure to 2-HOBA also attenuated molecular aging and extended longevity in C. elegans, increasing lifespan by more than 50% [22]. Together, these additional preclinical studies support the potential for 2-HOBA to have wide-ranging protective effects against oxidant-related disease and dysfunction.

A limitation of this first-in-human study is the relatively narrow age range of volunteers. Though older individuals were not excluded from participation in this trial, the enrolled cohort ranged in age from 20 to 40 years; this limits the generalizability of these findings to broader populations. Follow-up studies should specifically target older individuals to identify any unique adverse effects or pharmacokinetic properties in this population.

Conclusions

In summary, 2-HOBA acetate was safe and well-tolerated in single dose administration up to 825 mg in healthy human volunteers. The pharmacokinetic profile was reasonable, exhibiting fairly rapid absorption and elimination of 2-HOBA. Next steps include evaluating the safety and tolerability of multiple doses of 2-HOBA acetate in healthy individuals as well as older individuals more representative of the population segment at elevated risk for developing Alzheimer’s disease. We will also confirm in humans that 2-HOBA crosses the blood brain barrier, as has been previously demonstrated in rodents [11].

Abbreviations

2-HOBA:

2-hydroxybenzylamine

References

  1. Roberts LJ, Salomon RG, Morrow JD, Brame CJ. New developments in the isoprostane pathway: identification of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and characterization of their protein adducts. FASEB J. 1999;13(10):1157–68.

    Article  CAS  Google Scholar 

  2. Salomon RG, Miller DB, Zagorski MG, Coughlin DJ. Solvent-induced fragmentation of prostaglandin endoperoxides. New aldehyde products from PGH2 and a novel intramolecular 1,2-hydride shift during endoperoxide fragmentation in aqueous solution. J Am Chem Soc. 1984;106:6049–60.

    Article  CAS  Google Scholar 

  3. Zagol-Ikapitte I, Masterson TS, Amarnath V, Montine TJ, Andreasson KI, Boutaud O, et al. Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem. 2005;94(4):1140–5.

    Article  CAS  Google Scholar 

  4. Bernoud-Hubac N, Alam DA, Lefils J, Davies SS, Amarnath V, Guichardant M, et al. Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation. Biochim Biophys Acta. 2009;1791(4):307–13.

    Article  CAS  Google Scholar 

  5. Kirabo A, Fontana V, de Faria AP, Loperena R, Galindo CL, Wu J, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124(10):4642–56.

    Article  CAS  Google Scholar 

  6. Roychowdhury S, McMullen MR, Pritchard MT, Li W, Salomon RG, Nagy LE. Formation of gamma-ketoaldehyde-protein adducts during ethanol-induced liver injury in mice. Free Radic Biol Med. 2009;47(11):1526–38.

    Article  CAS  Google Scholar 

  7. Boutaud O, Ou JJ, Chaurand P, Caprioli RM, Montine TJ, Oates JA. Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers. J Neurochem. 2002;82(4):1003–6.

    Article  CAS  Google Scholar 

  8. Boutaud O, Montine TJ, Chang L, Klein WL, Oates JA. PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1–42. J Neurochem. 2006;96(4):917–23.

    Article  CAS  Google Scholar 

  9. Zagol-Ikapitte I, Amarnath V, Bala M, Roberts LJ, Oates JA, Boutaud O. Characterization of scavengers of gamma-ketoaldehydes that do not inhibit prostaglandin biosynthesis. Chem Res Toxicol. 2010;23(1):240–50.

    Article  CAS  Google Scholar 

  10. Koyama M, Obata Y, Sakamura S. Identification of hydroxybenzylamines in buckwheat seeds. Agri Biol Chem. 1971;35:1870–9.

    Article  CAS  Google Scholar 

  11. Zagol-Ikapitte IA, Matafonova E, Amarnath V, Bodine CL, Boutaud O, Tirona RG, et al. Determination of the pharmacokinetics and Oral bioavailability of Salicylamine, a potent gamma-Ketoaldehyde scavenger, by LC/MS/MS. Pharmaceutics. 2010;2(1):18–29.

    Article  CAS  Google Scholar 

  12. Davies SS, Bodine C, Matafonova E, Pantazides BG, Bernoud-Hubac N, Harrison FE, et al. Treatment with a gamma-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice. J Alzheimers Dis. 2011;27(1):49–59.

    Article  CAS  Google Scholar 

  13. Pitchford LM, Smith JD, Abumrad NN, Rathmacher JA, Fuller JC Jr. Acute and 28-day repeated dose toxicity evaluations of 2-hydroxybenzylamine acetate in mice and rats. Regul Toxicol Pharmacol. 2018.

  14. Fuller JC, Pitchford LM, Morrison RD, Daniels JS, Flynn CR, Abumrad NN, et al. In vitro safety pharmacology evaluation of 2-hydroxybenzylamine acetate. Food Chem Toxicol. 2018;121:541–548.

  15. Fuller JC, Pitchford LM, Abumrad NN, Rathmacher JA. Subchronic (90-day) repeated dose toxicity study of 2-hydroxybenzylamine acetate in rats. Regulatory Toxicology and Pharmacology. 2018;99:225–232.

  16. Fuller JC, Pitchford LM, Abumrad NN, Rathmacher JA. Subchronic (90-day) repeated dose oral toxicity study of 2-hydroxybenzylamine acetate in rabbit. Regul Toxicol Pharmacol. 2018;100:52–58.

  17. Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A. Translation of innovative designs into phase I trials. J Clin Oncol. 2007;25(31):4982–6.

    Article  Google Scholar 

  18. MTt R, Krishnan K, Rock CL, Normolle D, Vaerten MA, Peters-Golden M, et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst. 1997;89(15):1152–60.

    Article  Google Scholar 

  19. Pearson JN, Warren E, Liang LP, Roberts LJ 2nd, Patel M. Scavenging of highly reactive gamma-ketoaldehydes attenuates cognitive dysfunction associated with epileptogenesis. Neurobiol Dis. 2017;98:88–99.

    Article  CAS  Google Scholar 

  20. Wu J, Saleh MA, Kirabo A, Itani HA, Montaniel KR, Xiao L, et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest. 2016;126(1):50–67.

    Article  Google Scholar 

  21. Egnatchik RA, Brittain EL, Shah AT, Fares WH, Ford HJ, Monahan K, et al. Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension. Pulm Circ. 2017;7(1):186–99.

    Article  CAS  Google Scholar 

  22. Nguyen TT, Caito SW, Zackert WE, West JD, Zhu S, Aschner M, et al. Scavengers of reactive gamma-ketoaldehydes extend Caenorhabditis elegans lifespan and healthspan through protein-level interactions with SIR-2.1 and ETS-7. Aging (Albany NY). 2016;8(8):1759–80.

    Article  CAS  Google Scholar 

Download references

Funding

The study was supported by the National Institute On Aging of the National Institutes of Health under Award Number AG055184 and by CTSA award Number UL1 TR002243 from the National Center for Advancing Translational Sciences.

Availability of data and materials

The data for this research study was collected under informed consent of the volunteers. Thus, access to the data will be subject to approval by the Vanderbilt University Medical Center Institutional Review Board.

Author information

Authors and Affiliations

  1. Metabolic Technologies, Inc., Ames, IA, 50010, USA

    Lisa M. Pitchford, John A. Rathmacher & John C. Fuller Jr

  2. Department of Animal Science, Iowa State University, Ames, IA, 50010, USA

    John A. Rathmacher

  3. Sano Informed Prescribing Inc., Franklin, TN, 37067, USA

    J. Scott Daniels & Ryan D. Morrison

  4. Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy, Nashville, TN, 37204, USA

    Wendall S. Akers

  5. Department of Pharmacology, Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA

    Wendall S. Akers, L. Jackson Roberts, John A. Oates & Olivier Boutaud

  6. Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    Naji N. Abumrad

  7. Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    Venkataraman Amarnath & Patricia M. Currey

  8. Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

    L. Jackson Roberts & John A. Oates

Authors
  1. Lisa M. Pitchford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Rathmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John C. Fuller Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Scott Daniels
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryan D. Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wendall S. Akers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naji N. Abumrad
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Venkataraman Amarnath
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patricia M. Currey
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L. Jackson Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. John A. Oates
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Olivier Boutaud
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JAR, JCF, NNA, VA, LJR, JAO, and OB contributed to the conception and design of the study. PMC, JAO, and OB collected and/or interpreted the clinical data. JSD, RDM, and WSA performed and interpreted the pharmacokinetic analyses. LMP and JAR drafted the manuscript. JCF, JSD, WSA, NNA, JAO, and OB critically revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Lisa M. Pitchford.

Ethics declarations

Ethics approval and consent to participate

The study protocol was approved by the Vanderbilt University Institutional Review Board. All participants provided written informed consent before participating in the study.

Consent for publication

Not applicable.

Competing interests

JCF, LMP, and JAR are employed by and NNA is co-founder and part owner of Metabolic Technologies, Inc., which has executed an agreement for the rights to license the intellectual property for 2-hydroxybenzylamine from Vanderbilt University. JSD and RDM are employed by Sano Informed Prescribing, which received payment for services provided for this study. WSA received payment for the clinical pharmacokinetic analysis.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Figure S1 and Table S1. Mean exposure and pharmacokinetics of the primary metabolite of 2-HOBA, salicylic acid, after oral administration of 2-HOBA acetate. (DOCX 21 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pitchford, L.M., Rathmacher, J.A., Fuller, J.C. et al. First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers. BMC Pharmacol Toxicol 20, 1 (2019). https://doi.org/10.1186/s40360-018-0281-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40360-018-0281-7

Keywords

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us